Lecalpin

Lercanidipine hydrochloride, the active ingredient in Lecalpin, is a calcium channel blocker presented as an oral tablet for oral use. It is employed to lower elevated blood pressure in adult patients with hypertension.

GNH USA supplies Lecalpin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a dihydropyridine calcium channel blocker used in the management of high blood pressure conditions. - Hypertension: reduces systolic and diastolic blood pressure to target levels. - Essential hypertension: provides long‑lasting blood pressure control in primary hypertension. - Isolated systolic hypertension: helps lower elevated systolic pressure, especially in older adults.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate pain often occurring after the first dose. - Flushing: sensation of warmth and redness, especially on the face. - Peripheral edema: swelling of the ankles or feet due to fluid accumulation. - Dizziness: light‑headed feeling, particularly when standing quickly. - Tachycardia: increased heart rate, usually mild. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that may cause fainting. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, itching, or hives. - Angioedema: swelling of lips, tongue, or throat. - Cardiac arrhythmia: irregular heart rhythm.

Before initiating therapy with lercanidipine, consider the following safety measures. - Blood pressure monitoring: regularly check to avoid excessive hypotension. - Hepatic impairment: use with caution in patients with liver dysfunction. - Elderly patients: start at lower doses and monitor for dizziness. - Concomitant antihypertensives: adjust doses to prevent additive blood pressure lowering. - Severe aortic stenosis: contraindicated due to risk of reduced cardiac output. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels and risk of hypotension. - Concomitant use with other potent antihypertensives: can cause excessive blood pressure drop. - Grapefruit juice: enhances absorption leading to higher drug exposure.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness. - Diuretics: may augment antihypertensive effect, requiring dose adjustment. - Beta‑blockers: combined use may increase risk of bradycardia. - NSAIDs: may attenuate blood pressure‑lowering effect. - Alcohol: can increase dizziness and hypotension risk.